European Headache Federation recommendations for placebo and nocebo terminology.
Author
Mitsikostas, Dimos DBlease, Charlotte
Carlino, Elisa
Colloca, Luana
Geers, Andrew L
Howick, Jeremy
Evers, Andrea W M
Flaten, Magne A
Kelley, John M
Kirsch, Irving
Klinger, Regine
MaassenVanDenBrink, Antoinette
Moerman, Daniel E
Sfikakis, Petros P
Vase, Lene
Wager, Tor D
Benedetti, Fabrizio
Date
2020-09-25Journal
The journal of headache and painPublisher
Springer NatureType
Article
Metadata
Show full item recordAbstract
BACKGROUND AND AIM: Despite recent publications, practitioners remain unfamiliar with the current terminology related to the placebo and nocebo phenomena observed in clinical trials and practice, nor with the factors that modulate them. To cover the gap, the European Headache Federation appointed a panel of experts to clarify the terms associated with the use of placebo in clinical trials. METHODS: The working group identified relevant questions and agreed upon recommendations. Because no data were required to answer the questions, the GRADE approach was not applicable, and thus only expert opinion was provided according to an amended Delphi method. The initial 12 topics for discussion were revised in the opinion of the majority of the panelists, and after a total of 6 rounds of negotiations, the final agreement is presented. RESULTS/RECOMMENDATIONS: Two primary and mechanism-based recommendations are provided for the results of clinical trials: [1] to distinguish the placebo or nocebo response from the placebo or nocebo effect; and [2] for any favorable outcome observed after placebo administration, the term "placebo response" should be used, and for any unfavorable outcome recorded after placebo administration, the term "nocebo response" should be used (12 out of 17 panelists agreed, 70.6% agreement). The placebo or nocebo responses are attributed to a set of factors including those that are related to the medical condition (e.g. natural history, random comorbidities, etc.), along with idiosyncratic ones, in which the placebo or nocebo effects are attributed to idiosyncratic, or nonspecific mechanisms, exclusively (e.g. expectation, conditioning, observational learning etc.). To help investigators and practitioners, the panel summarized a list of environmental factors and idiosyncratic dynamics modulating placebo and nocebo effects. Some of them are modifiable, and investigators or physicians need to know about them in order to modify these factors appropriately to improve treatment. One secondary recommendation addresses the use of the terms "placebo" and "nocebo" ("placebos" and "nocebos" in plural), which refer to the triggers of the placebo/nocebo effects or responses, respectively, and which are inert agents or interventions that should not be confused with the placebo/nocebo responses or effects themselves (all panelists agreed, 100% agreement). CONCLUSION: The working group recommends distinguishing the term response from effect to describe health changes from before to after placebo application and to distinguish the terms placebo(s) or nocebo(s) from the health consequences that they cause (placebo/nocebo responses or effects).Identifier to cite or link to this item
http://hdl.handle.net/10713/13851ae974a485f413a2113503eed53cd6c53
10.1186/s10194-020-01178-3
Scopus Count
Collections
Related articles
- Nocebo and placebo modulation of hypobaric hypoxia headache involves the cyclooxygenase-prostaglandins pathway.
- Authors: Benedetti F, Durando J, Vighetti S
- Issue date: 2014 May
- What Should Clinicians Tell Patients about Placebo and Nocebo Effects? Practical Considerations Based on Expert Consensus.
- Authors: Evers AWM, Colloca L, Blease C, Gaab J, Jensen KB, Atlas LY, Beedie CJ, Benedetti F, Bingel U, Büchel C, Bussemaker J, Colagiuri B, Crum AJ, Finniss DG, Geers AL, Howick J, Klinger R, Meeuwis SH, Meissner K, Napadow V, Petrie KJ, Rief W, Smeets I, Wager TD, Wanigasekera V, Vase L, Kelley JM, Kirsch I, Consortium of Placebo Experts
- Issue date: 2021
- Implications of Placebo and Nocebo Effects for Clinical Practice: Expert Consensus.
- Authors: Evers AWM, Colloca L, Blease C, Annoni M, Atlas LY, Benedetti F, Bingel U, Büchel C, Carvalho C, Colagiuri B, Crum AJ, Enck P, Gaab J, Geers AL, Howick J, Jensen KB, Kirsch I, Meissner K, Napadow V, Peerdeman KJ, Raz A, Rief W, Vase L, Wager TD, Wampold BE, Weimer K, Wiech K, Kaptchuk TJ, Klinger R, Kelley JM
- Issue date: 2018
- The Placebo and Nocebo Phenomena: Their Clinical Management and Impact on Treatment Outcomes.
- Authors: Chavarria V, Vian J, Pereira C, Data-Franco J, Fernandes BS, Berk M, Dodd S
- Issue date: 2017 Mar
- Clinical relevance of contextual factors as triggers of placebo and nocebo effects in musculoskeletal pain.
- Authors: Rossettini G, Carlino E, Testa M
- Issue date: 2018 Jan 22